Tissue distribution of humanized anti-human Fas monoclonal antibody (R-125224) based on fas antigen-antibody reaction in collagen-induced arthritis monkeys

被引:7
作者
Saito, Motoko
Yoshigae, Yasushi
Nakayama, Junichi
Ogawa, Yukie
Ohtsuki, Masahiko
Kurihara, Atsushi
Ikeda, Toshihiko
机构
[1] Sankyo Co Ltd, Drug Metab Lab, Shinagawa Ku, Tokyo 1408710, Japan
[2] Sankyo Co Ltd, Pharmacokinet Res Lab, Shinagawa Ku, Tokyo 1408710, Japan
[3] Sankyo Co Ltd, Biol Res Labs, Shinjuku Ku, Tokyo 1408710, Japan
[4] Sankyo Co Ltd, R&D Project Management Dept, Shinagawa Ku, Tokyo 1408710, Japan
[5] Daiichi Sankyo Pharma Dev, Global Project Management, Edison, NJ 08837 USA
关键词
tissue distribution; anti-Fas monoclonal antibody; collagen-induced arthritis; monkey; pharmacokinetics;
D O I
10.1016/j.lfs.2007.02.043
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
R-125224 is a novel humanized anti-human Fas monoclonal antibody prepared from HFE7A, which is a monoclonal mouse IgG anti-Fas antibody, by grafting the mouse complementarity-determining regions to human IgG, presently being developed as a drug for treatment of rheumatoid arthritis. In the present study, we investigated the tissue distribution of radioactivity in cynomolgus monkeys with collagen-induced arthritis at the arm joint (CIA monkeys) after intravenous administration of I-125-labeled R-125224 (I-125-R-125224). At 168 h after administration, we observed a high radioactivity in the bone marrow, thymus, lungs, liver, adrenals, spleen, ovaries, axillary lymph node and mesenteric lymph node compared to the radioactivity in the plasma. These tissues and organs in human are reported to express Fas antigen, strongly suggesting a specific binding of I-125-R-125224 to Fas antigen in cynomolgus monkeys. Semi-micro autoradioluminograms of anti joint showed that radioactivity is detected in pharmacological site, such as the bone marrow and articular cavity at 168 h. The kinetics in binding of R-125224 to activated monkey lymphocytes and hepatocytes was also investigated. Kd values of activated lymphocytes and hepatocytes were 1.51 +/- 0.08 and 0.60 +/- 0.11 nM, respectively, which were similar to those values in human lymphocytes and hepatocytes, demonstrating that R-I 25224 cross-reacts with the monkey Fas antigen. (c) 2007 Published by Elsevier Inc.
引用
收藏
页码:2005 / 2014
页数:10
相关论文
共 23 条
  • [1] IMMUNIZATION AGAINST HETEROLOGOUS TYPE-II COLLAGEN INDUCES ARTHRITIS IN MICE
    COURTENAY, JS
    DALLMAN, MJ
    DAYAN, AD
    MARTIN, A
    MOSEDALE, B
    [J]. NATURE, 1980, 283 (5748) : 666 - 668
  • [2] Humanization of the mouse anti-Fas antibody HFE7A and crystal structure of the humanized HFE7A Fab fragment
    Haruyama, H
    Ito, S
    Miyadai, K
    Takahashi, T
    Kawaida, R
    Takayama, T
    Hanzawa, H
    Hata, T
    Yamaguchi, J
    Yoshida-Kato, H
    Ichikawa, K
    Ohsumi, J
    Yonehara, S
    Serizawa, N
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2002, 25 (12) : 1537 - 1545
  • [3] A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity
    Ichikawa, K
    Yoshida-Kato, H
    Ohtsuki, M
    Ohsumi, J
    Yamaguchi, J
    Takahashi, S
    Tani, Y
    Watanabe, M
    Shiraishi, A
    Nishioka, K
    Yonehara, S
    Serizawa, N
    [J]. INTERNATIONAL IMMUNOLOGY, 2000, 12 (04) : 555 - 562
  • [4] Fas-induced in vivo apoptosis in bone marrow:: Anti-Fas mAb-induced elimination and successive proliferation of Fas-expressing cells especially those of myeloid lineage
    Inazawa, Y
    Yonehara, S
    [J]. CELL STRUCTURE AND FUNCTION, 1999, 24 (03) : 151 - 159
  • [5] THE POLYPEPTIDE ENCODED BY THE CDNA FOR HUMAN CELL-SURFACE ANTIGEN FAS CAN MEDIATE APOPTOSIS
    ITOH, N
    YONEHARA, S
    ISHII, A
    YONEHARA, M
    MIZUSHIMA, S
    SAMESHIMA, M
    HASE, A
    SETO, Y
    NAGATA, S
    [J]. CELL, 1991, 66 (02) : 233 - 243
  • [6] Therapeutic effect of novel anti-human Fas antibody HFE7A on graft-versus-host disease model
    Kuwahara, H
    Tani, Y
    Ogawa, Y
    Takaichi, Y
    Shiraishi, A
    Ohtsuki, M
    [J]. CLINICAL IMMUNOLOGY, 2001, 99 (03) : 340 - 346
  • [7] LEITHAUSER F, 1993, LAB INVEST, V69, P415
  • [8] MASTUNO H, 2002, J RHEUMATOL, V29, P1609
  • [9] Matsuno H, 1998, ARTHRITIS RHEUM, V41, P2014, DOI 10.1002/1529-0131(199811)41:11<2014::AID-ART17>3.3.CO
  • [10] 2-K